News Conference News EAS 2020 Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank Michael O'Riordan October 07, 2020
News Daily News High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention Michael O'Riordan August 11, 2020
News Daily News Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES Michael O'Riordan May 04, 2020
News Daily News Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes Michael O'Riordan January 14, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020